FIG 1.
Reduced peak saliva shedding, yet similar numbers of viral haplotypes and nucleotide diversity between HCMV-infected glycoprotein B vaccinees and placebo recipients. Peak plasma viral loads (A) as well as the peak magnitudes of virus shed in saliva (B), urine (C), and vaginal fluid (D) were compared between 11 gB vaccinees and 22 placebo recipients (samples not available from each compartment for each participant). Plasma (A), urine (C), and vaginal fluid (D) viral loads were not statistically different between HCMV-infected placebo recipients and gB/MF59 vaccinees, though there was reduced HCMV shedding in the saliva of vaccinees (B). Using SNAPP NGS data, the peak number of unique viral haplotypes (E) as well as peak nucleotide diversity (π) (F) were assessed for viral DNA amplified at the gB locus for 3 tissue culture virus isolates (TC virus), 13 placebo recipients, 5 gB/MF59 vaccinees, and 4 seropositive chronically HCMV-infected individuals (Sero+). (G) The magnitudes of nucleotide diversity resulting in synonymous (πS) versus nonsynonymous changes (πN) were compared. Horizontal bars indicate the median values for each group. *, P < 0.05 according to statistical tests: viral load, exact Wilcoxon rank sum test; haplotypes and π, Kruskal-Wallis test plus post hoc exact Wilcoxon rank sum test; πS versus πN, Wilcoxon signed-rank test.